Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PetMed ExpressPETS 56 Intrinsic Value: Projected FCF is $3.31 as of Sep. 21, 2026. GuruFocus rates PETS with a GF Score™ of 56/100 and a GF Value™ of $2.54 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 347 Healthcare Providers & Services companies, PetMed Express ranks better than 83% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-21), PetMed Express's Intrinsic Value: Projected FCF is $3.31. The stock price of PetMed Express is $1.60. Therefore, PetMed Express's Price-to-Intrinsic-Value-Projected-FCF of today is 0.5.
The historical rank and industry rank for PetMed Express's Intrinsic Value: Projected FCF or its related term are showing as below:
PETS'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.28 Med: 1.25 Max: 3.03
Current: 0.48
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of PetMed Express was 3.03. The lowest was 0.28. And the median was 1.25.
PETS's Price-to-Projected-FCF is ranked better than 83% of 347
companies
in the Healthcare Providers & Services industry
Industry Median: 1.05
vs PETS: 0.48
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
PetMed Express's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
1.60
/
3.3074923125341
=
0.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PetMed Express Intrinsic Value: Projected FCF Related Terms
PetMed Express Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for PetMed Express's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PETS vs BHIC, SCNX, PMHS: Intrinsic Value: Projected FCF Comparison
For the Pharmaceutical Retailers subindustry, PetMed Express's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PetMed Express Price-to-Projected-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PetMed Express's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where PetMed Express's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $3.31 mean?
PetMed Express (PETS) has a Intrinsic Value: Projected FCF of $3.31 as of Sep. 21, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on PetMed Express and its competitors. According to the industry distribution chart, PetMed Express ranks #59 out of 347 companies in the Healthcare Providers & Services industry, placing it in the top 17%.
Is PetMed Express' Intrinsic Value: Projected FCF too high?
PetMed Express' current Intrinsic Value: Projected FCF is $3.31. The Healthcare Providers & Services industry median Intrinsic Value: Projected FCF is 1.05. PetMed Express' value of $3.31 is 215.2% above this industry median. Based on the distribution chart, PetMed Express ranks #59 out of 347 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, PetMed Express has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PetMed Express' Intrinsic Value: Projected FCF compare to BHIC and SCNX?
According to the Healthcare Providers & Services industry distribution chart, PetMed Express ranks #59 out of 347 companies for Intrinsic Value: Projected FCF. This places PetMed Express in the top 17% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.05. PetMed Express' value of $3.31 is 215.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Healthcare Providers & Services company?
The median Intrinsic Value: Projected FCF among Healthcare Providers & Services companies is 1.05, based on 347 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PetMed Express's current Intrinsic Value: Projected FCF of $3.31 is 215.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on PetMed Express and its competitors. For the Healthcare Providers & Services industry, the median Intrinsic Value: Projected FCF is 1.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PetMed Express's current Intrinsic Value: Projected FCF is $3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PetMed Express stock overvalued right now?
Based on GuruFocus' analysis, PetMed Express (PETS) is currently considered Possible Value Trap. The stock's GF Value™ is $2.54, compared to a current price of $1.60 — trading 37% below its estimated fair value. The current Intrinsic Value: Projected FCF is $3.31 and 215.2% above the Healthcare Providers & Services industry median of 1.05. PetMed Express' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For PetMed Express (PETS), the current Intrinsic Value: Projected FCF is $3.31 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PetMed Express (PETS) Overvalued in 2026?
Based on GuruFocus' analysis, PetMed Express stock appears to be undervalued.
The current stock price of $1.60 is trading 37% below its estimated GF Value™ of $2.54.
GuruFocus considers PetMed Express to be Possible Value Trap.
Key valuation signals for PETS:
Intrinsic Value: Projected FCF: $3.31
GF Value™: $2.54 vs. price of $1.60 (37% below fair value)
Industry Position: 215.2% above the Healthcare Providers & Services median (#59 of 347)
No single metric tells the full story. See the PETS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.
56GF Score
Get the complete analysis for PETS
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PETS has been successfully added to your 
